John E. Imhoff - 23 Sep 2024 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GTHP
Reported as of: 23 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2024, 16:30:20 UTC
Prior SEC filing: 22 Aug 2024
Next SEC filing: 25 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ John E. Imhoff

Key filing fact

John E. Imhoff filed Form 4 for GUIDED THERAPEUTICS INC (GTHP) on 02 Oct 2024.

Key facts

This page summarizes John E. Imhoff's Form 4 filing for GUIDED THERAPEUTICS INC (GTHP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Oct 2024, 16:30.

Change

Previous filing in this sequence was filed on 22 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GTHP transaction

Common Stock

Purchase

Transaction value
Shares: +1,666,667
Change %: +31%
Price
Shares after: 7,075,898
Date: 23 Sep 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GTHP transaction Derivative

Warrants

Purchase

Transaction value
Shares: +1,666,667
Change %
Price
Shares after: 1,666,667
Date: 23 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,666,667
Exercise price: $0.1200
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share.